ReGenX Biosciences

A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.

Launch date

2009

Employees

Market cap

Enterprise valuation

€391m (Public information from Sep 2024)

Rockville Maryland (HQ)

http://regenxbio.com

https://twitter.com/regenxbio http://www.facebook.com/pages/REGENX-Biosciences-LLC/89894384909 https://www.linkedin.com/company/regenx

View job openings

Authorizing premium user...